title: Letter by Kan et al regarding Article, "randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart failure (WATCH) trial".
authors.forename: Li-Ping
authors.initials: LP
authors.lastname: Kan
authors.forename: Kai-Min
authors.initials: KM
authors.lastname: Chu
authors.forename: Gen-Min
authors.initials: GM
authors.lastname: Lin
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001241:Aspirin / Q000008:administration & dosage; D002908:Chronic Disease; D000077144:Clopidogrel; D003643:Death; D004311:Double-Blind Method; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006333:Heart Failure / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction; D020521:Stroke; D013318:Stroke Volume; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D014859:Warfarin / Q000008:administration & dosage
chemical_list: D005343:Fibrinolytic Agents; D014859:Warfarin; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin